In This Article:
GE HealthCare Technologies Inc. GEHC recently announced the U.S. launch of Flyrcado (flurpiridaz F 18) injection at the ongoing American College of Cardiology (ACC) Annual Scientific Session & Expo. It also plans to unveil the latest version of CASE (Cardiac Assessment System for Stress Testing), powered by its CardioSoft technology, at the ACC.
GE HealthCare also plans to showcase CardIQ Suite (an integrated workflow for the seamless review of calcium scoring and cardiac computed tomography angiography data) and its recently launched AltiX AI.i edition of Mac-Lab, CardioLab and ComboLab editions.
GEHC aims to highlight its strategy to leverage AI to help increase efficiency and enable seamless integration of data across the cardiology care pathway by showcasing its latest AI-powered innovations.
The latest launch is expected to significantly strengthen GE HealthCare’s Cardiology Solutions unit, thus boosting its overall business.
Significance of GE HealthCare’s Latest Launch
Per GE HealthCare’s estimates, around six million myocardial perfusion imaging (MPI) procedures are undertaken each year in the United States to show blood flow through the heart muscle and evaluate the presence, extent and degree of myocardial ischemia or infarction. Positron emission tomography (PET) is currently the most effective form of MPI for detecting coronary artery disease (CAD) and is recommended for a wide range of patients, including those considered more challenging to diagnose, over single-photon emission computed tomography (SPECT) MPI.
GEHC further stated that the FDA approved Flyrcado for patients with known or suspected CAD in 2024. This is expected to deliver higher diagnostic efficacy, unlike SPECT MPI, the predominant procedure used in nuclear cardiology at present.
GE HealthCare’s management believes that the launch of Flyrcado represents a significant advancement in cardiac care, providing a new, highly effective diagnostic tool for those with known or suspected CAD.
Additionally, Flyrcado has been granted traditional pass-through payment status by the U.S. Centers for Medicare and Medicaid (CMS). The receipt of pass-through status from the CMS, effective April 1, secures a drug-specific Healthcare Common Procedure Coding System or HCPCS billing code and coverage for traditional Medicare beneficiaries. Pass-through payment status will likely enable CMS to provide separate payments for radiopharmaceutical and PET-CT scan, when performed with Flyrcado in the hospital outpatient setting.
Industry Prospects in Favor of GEHC
Per a report by Grand View Research, the global coronary heart disease diagnostic imaging device market was estimated to be $2 billion in 2024 and is anticipated to witness a CAGR of 6.6% between 2025 and 2030. Factors like the increasing prevalence of CAD and the rising adoption of early diagnostic techniques are likely to drive the market.